Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

PT-141

Bremelanotide, Vyleesi

Quick Stats
Studies 74
Trials 10
2024 pubmed 1 citations

First-time orgasm in a young man with lifelong anorgasmia after flibanserin use: a case report.

Saffati. Gal G; Naeem. Taher T; Kaaki. Basil B; Khera. Mohit M

Key Findings

  • Off‑label flibanserin led to a first orgasm after 28‑32 doses over 4 weeks in one male patient.
  • Side effects included nocturia and insomnia.
  • Only a marginal improvement in erectile function scores was observed; overall sexual satisfaction did not increase.

Practical Outcomes

  • This report does not involve the peptide PT‑141, so it offers no direct guidance for using that peptide. It suggests flibanserin might have some effect on male anorgasmia, but the evidence is limited to one case and comes with side effects, so it is not a reliable protocol for biohackers seeking actionable peptide strategies.

Summary

A single case report describes a 28‑year‑old man with lifelong anorgasmia who finally had an orgasm after taking the female‑focused drug flibanserin for about a month. He also reported nighttime urination and trouble sleeping, and his overall sexual satisfaction barely changed.

Abstract

Anorgasmia is a poorly understood phenomenon defined as either a lifelong or acquired consistent inability to achieve ejaculation. Despite the prevalence of anorgasmia, there is currently no established treatment for the condition. To report a unique case of a patient with lifelong anorgasmia who was able to achieve his first orgasm with off-label use of flibanserin. The present case study relies on the patient's self-report and a review of the relevant literature. The patient provided written informed consent. A 28-year-old male presented to our office with complaints of lifelong anorgasmia, without any signs of erectile dysfunction. He reported good libido and energy levels and denied any urinary symptoms or history of depression. The patient failed medical management with numerous off-label medications, including bupropion and bremelanotide. Despite having received 4 or 5 sex therapy sessions over 3 months, the patient reported that this treatment approach was not effective. Off-label use of flibanserin was then initiated, and after 28 to 32 doses over 4 weeks, he achieved his first orgasm. Notably, the patient experienced nocturia and insomnia. The follow-up International Index of Erectile Function score marginally improved by 2 points without any improvement in the overall satisfaction subdomain. This case highlights the challenges of managing anorgasmia and anejaculation in a young male patient. A stepwise approach involving pharmacotherapy and sex therapy was not successful. However, the off-label use of flibanserin ultimately resulted in the patient achieving his first orgasm, albeit with some side effects. Further studies are needed to evaluate the efficacy and safety of flibanserin in men for this indication.

Study Information

Provider

pubmed

Year

2024

Date

2024-01-11T00:00:00.000Z

DOI

10.1093/sexmed/qfad066

Citations

1

References

10